Cargando…
Levofloxacin-Induced Acute Hyperpigmentation Changes in a Chronic Kidney Disease Patient
Medication-induced cutaneous hyperpigmentation has variable clinical presentations and is dependent on the specific drug involved. Most commonly, an attentive patient observes such changes early in the course; when missed by the patient, such changes are usually noted by an observant clinician. Clin...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669357/ https://www.ncbi.nlm.nih.gov/pubmed/33224201 http://dx.doi.org/10.1155/2020/6186471 |
_version_ | 1783610552282513408 |
---|---|
author | Patil, Shakuntala S. Patil, Sachin M. Campbell, Ryan Singh, Manisha Plotkin, Matthew |
author_facet | Patil, Shakuntala S. Patil, Sachin M. Campbell, Ryan Singh, Manisha Plotkin, Matthew |
author_sort | Patil, Shakuntala S. |
collection | PubMed |
description | Medication-induced cutaneous hyperpigmentation has variable clinical presentations and is dependent on the specific drug involved. Most commonly, an attentive patient observes such changes early in the course; when missed by the patient, such changes are usually noted by an observant clinician. Clinical diagnosis can be challenging if the patient is on multiple medications because other causes must be excluded. This condition occurs via multiple mechanisms. Frequently, the pigmentary change is reversible with discontinuation of the drug. Causative medications include nonsteroidal; anti-inflammatory agents, antimalarials, antibiotics, psychotropics, amiodarone, and chemotherapeutic agents. The; antimicrobials responsible for hyperpigmentation are antimalarials, tetracyclines, tigecycline, dapsone, rifampicin, and antiretrovirals such as zidovudine. Sunlight exposure can worsen the pigmentation seen with some of the above antimicrobials (e.g., dapsone). Here, we describe an older adult white woman presenting with acute cutaneous; hyperpigmentation of the bilateral lower extremities while on levofloxacin therapy. Hyperpigmentation resolved after cessation of the agent. Our case highlights this unique acute presentation after only a few days of oral levofloxacin. |
format | Online Article Text |
id | pubmed-7669357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-76693572020-11-19 Levofloxacin-Induced Acute Hyperpigmentation Changes in a Chronic Kidney Disease Patient Patil, Shakuntala S. Patil, Sachin M. Campbell, Ryan Singh, Manisha Plotkin, Matthew Case Rep Med Case Report Medication-induced cutaneous hyperpigmentation has variable clinical presentations and is dependent on the specific drug involved. Most commonly, an attentive patient observes such changes early in the course; when missed by the patient, such changes are usually noted by an observant clinician. Clinical diagnosis can be challenging if the patient is on multiple medications because other causes must be excluded. This condition occurs via multiple mechanisms. Frequently, the pigmentary change is reversible with discontinuation of the drug. Causative medications include nonsteroidal; anti-inflammatory agents, antimalarials, antibiotics, psychotropics, amiodarone, and chemotherapeutic agents. The; antimicrobials responsible for hyperpigmentation are antimalarials, tetracyclines, tigecycline, dapsone, rifampicin, and antiretrovirals such as zidovudine. Sunlight exposure can worsen the pigmentation seen with some of the above antimicrobials (e.g., dapsone). Here, we describe an older adult white woman presenting with acute cutaneous; hyperpigmentation of the bilateral lower extremities while on levofloxacin therapy. Hyperpigmentation resolved after cessation of the agent. Our case highlights this unique acute presentation after only a few days of oral levofloxacin. Hindawi 2020-11-07 /pmc/articles/PMC7669357/ /pubmed/33224201 http://dx.doi.org/10.1155/2020/6186471 Text en Copyright © 2020 Shakuntala S. Patil et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Patil, Shakuntala S. Patil, Sachin M. Campbell, Ryan Singh, Manisha Plotkin, Matthew Levofloxacin-Induced Acute Hyperpigmentation Changes in a Chronic Kidney Disease Patient |
title | Levofloxacin-Induced Acute Hyperpigmentation Changes in a Chronic Kidney Disease Patient |
title_full | Levofloxacin-Induced Acute Hyperpigmentation Changes in a Chronic Kidney Disease Patient |
title_fullStr | Levofloxacin-Induced Acute Hyperpigmentation Changes in a Chronic Kidney Disease Patient |
title_full_unstemmed | Levofloxacin-Induced Acute Hyperpigmentation Changes in a Chronic Kidney Disease Patient |
title_short | Levofloxacin-Induced Acute Hyperpigmentation Changes in a Chronic Kidney Disease Patient |
title_sort | levofloxacin-induced acute hyperpigmentation changes in a chronic kidney disease patient |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669357/ https://www.ncbi.nlm.nih.gov/pubmed/33224201 http://dx.doi.org/10.1155/2020/6186471 |
work_keys_str_mv | AT patilshakuntalas levofloxacininducedacutehyperpigmentationchangesinachronickidneydiseasepatient AT patilsachinm levofloxacininducedacutehyperpigmentationchangesinachronickidneydiseasepatient AT campbellryan levofloxacininducedacutehyperpigmentationchangesinachronickidneydiseasepatient AT singhmanisha levofloxacininducedacutehyperpigmentationchangesinachronickidneydiseasepatient AT plotkinmatthew levofloxacininducedacutehyperpigmentationchangesinachronickidneydiseasepatient |